Drug intelligence / Profile preview

SIR-T CD33

Development stage: Preclinical
Lead developer: Angeles Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

SIR-T CD33 is an investigational cell therapy being developed by Angeles Therapeutics for the treatment of CD33-positive malignancies. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR-T) platform, which involves engineering T cells with a modular receptor designed to mimic natural T-cell signaling pathways for improved activation and persistence. By targeting the transmembrane protein CD33, which is highly expressed on myeloid cells and leukemic blasts, SIR-T CD33 aims to selectively identify and eliminate cancerous cells in conditions such as acute myeloid leukemia (AML). The program is currently in the discovery stage of development.

Other names: SIR-T CD33

Targets

CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on SIR-T CD33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-T CD33.

Explore the full profile